GLP1 Academy

Research horizon · October 2026

What's Next for GLP-1s?

The science shaping the next generation of metabolic and longevity medicine.

By GLP1 Academy · Brought to you by Longevity Academy · 11 min read · Reviewed against published trial results

Key points

  • Weight loss appears to be the first chapter, not the whole story. Research is moving toward protecting the heart, kidneys, liver and brain.
  • The field is becoming 'incretin and metabolic medicine': dual and triple hormone agonists, GLP-1/amylin combinations and oral small molecules.
  • Muscle preservation is emerging as the central open problem — the goal is the ratio of fat lost to functional tissue preserved, not pounds alone.
  • The longevity claim is still a hypothesis. In the evoke and evoke+ trials, oral semaglutide did not slow Alzheimer's progression.

For most people, the GLP-1 story began with weight loss. Semaglutide and tirzepatide demonstrated that altering appetite and metabolic signaling pharmacologically could produce weight loss that previously required bariatric surgery.

As of October 2026, weight loss increasingly looks like only the first chapter. Research has moved well beyond traditional GLP-1 receptor agonists toward oral drugs, dual and triple hormone agonists, GLP-1/amylin combinations, higher-potency formulations, organ-specific indications, and strategies designed to preserve muscle while reducing excess fat.

The underlying scientific strategy is consistent across all of it: manipulate multiple complementary metabolic signaling pathways at the same time. What follows is what that shift looks like in the trials themselves.

The trials at a glance

Nine studies that define the current moment. Status is as of October 2026.

SELECT

Semaglutide in obesity or overweight without diabetes, with existing cardiovascular disease

About 20% fewer major cardiovascular events (HR 0.80) in 17,604 adults

Approved indication

FLOW

Semaglutide in type 2 diabetes with chronic kidney disease

24% lower risk of major kidney events; 29% lower cardiovascular death

Approved indication

ESSENCE

Semaglutide in MASH with moderate-to-advanced liver fibrosis

62.9% vs 34.3% achieved steatohepatitis resolution at 72 weeks

Accelerated FDA approval (Aug 2025)

SOUL

50 mg oral semaglutide in type 2 diabetes at high cardiovascular risk

Cardiovascular events 12.0% vs 13.8% (HR 0.86) in 9,650 adults

Under FDA review

SURMOUNT-1 (3-yr)

Tirzepatide in obesity with prediabetes, 176 weeks

Diabetes onset 1.3% vs 13.3%; weight loss ~19.7% at highest dose

Approved drug; prevention data

REDEFINE 1

CagriSema (cagrilintide + semaglutide) in overweight or obesity

Weight loss statistically superior to placebo (3,417 adults)

Regulatory submissions begun

TRIUMPH-2 / -3

Retatrutide, a GIP/GLP-1/glucagon triple agonist

20.8% and 22.6% average weight loss at 80 weeks

Investigational; filing planned Q1 2027

evoke / evoke+

Oral semaglutide in early symptomatic Alzheimer's disease

No significant slowing of clinical progression (3,808 adults)

Negative

COURAGE

Semaglutide plus muscle-preserving antibodies

~35% of weight loss was lean mass; combinations spared 50-80% of it

Phase 2 interim

1. Triple agonists may push weight loss further

Retatrutide, an investigational once-weekly injection from Eli Lilly, activates three receptors at once: GIP, GLP-1 and glucagon. Adding glucagon is the part that makes it different. Glucagon signaling increases energy expenditure, so the medication is not only reducing appetite — it is also nudging the number of calories the body burns.

Two phase 3 trials reported results in 2026. In TRIUMPH-2, which enrolled 1,152 adults living with obesity or overweight and type 2 diabetes, participants who received the 12 mg dose lost an average of 20.8% of their body weight over 80 weeks. In TRIUMPH-3, which enrolled 1,949 adults with severe obesity and cardiovascular disease, the same dose produced an average reduction of 22.6% over the same period.7, 8

The company has said it plans to file a Biologics License Application in the first quarter of 2027. Retatrutide remains investigational and is not approved by the FDA. A larger average weight reduction on a trial report is not the same thing as a better treatment for a particular person; tolerability, muscle loss, access and long-term safety all matter, and long-term outcome data for retatrutide do not exist yet.

2. Amylin could become GLP-1's next major partner

Amylin is a hormone released by the pancreas alongside insulin. It slows stomach emptying, promotes feelings of fullness and reduces post-meal glucagon. Because it works through different pathways than GLP-1, the two mechanisms are complementary rather than duplicative.

CagriSema pairs cagrilintide, a long-acting amylin analogue, with semaglutide. In REDEFINE 1, a phase 3 trial that randomized 3,417 adults with overweight or obesity, weight loss with the combination was statistically superior to placebo and to each component alone.9 Novo Nordisk has begun the regulatory submissions that follow from those results.

A newer approach puts both mechanisms in a single molecule. Zenagamtide, previously called amycretin, is a unimolecular agonist of GLP-1 and amylin receptors. In a 262-person phase 2 dose-finding trial in adults with type 2 diabetes, weight loss reached 14.6% at 36 weeks on the highest dose tested, and the program advanced into phase 3.10 A once-daily oral version is also being studied.

3. Treatment is moving from injections toward pills

Oral semaglutide is already approved at a low dose for type 2 diabetes, but it is a demanding medication to make into a tablet: the peptide is easily destroyed in the gut and is absorbed only with a specific absorption enhancer, taken on an empty stomach with a small amount of water. Small-molecule agonists sidestep that problem entirely because they are not peptides.

The SOUL trial was the pivotal test. Among 9,650 adults with type 2 diabetes at high cardiovascular risk, a 50 mg once-daily oral semaglutide tablet produced a statistically significant reduction in major adverse cardiovascular events: 12.0% of participants on the drug versus 13.8% on placebo, a hazard ratio of 0.86.5 The FDA is reviewing that application.

The practical significance is mostly about adherence and acceptance. A meaningful share of people who start injectable therapy stop within the first year, and an oral option removes a barrier for those who cannot or will not inject. It also matters for scale: pills are easier to manufacture, distribute and dose than refrigerated pens.

4. The goal is shifting from weight loss to disease modification

This is the deepest change in the field. Cardiovascular outcome trials turned GLP-1 therapies from weight-loss medications into drugs with organ-level indications. In SELECT, 17,604 adults with cardiovascular disease and overweight or obesity but no diabetes saw roughly a 20% relative reduction in major adverse cardiovascular events on semaglutide.1 In FLOW, a trial of 3,533 adults with type 2 diabetes and chronic kidney disease, semaglutide lowered the risk of the primary composite kidney outcome by 24% and death from cardiovascular causes by 29%.2

The liver followed. In part 1 of the phase 3 ESSENCE trial, once-weekly semaglutide 2.4 mg produced significantly higher rates of steatohepatitis resolution without worsening fibrosis (62.9% versus 34.3% on placebo) and fibrosis improvement without worsening steatohepatitis (36.8% versus 22.4%) at 72 weeks.4 In August 2025, the FDA approved Wegovy for MASH in adults with moderate-to-advanced fibrosis under the accelerated approval pathway.3

The pattern across these trials is that the benefit shows up in tissues that were never the original target. That is why the same molecule is now being tested in sleep apnea, heart failure with preserved ejection fraction, chronic kidney disease, liver disease and addiction-related indications.

5. Prevention could become a major use case

In the three-year SURMOUNT-1 analysis, adults who had both obesity and prediabetes and received tirzepatide for 176 weeks were far less likely to be diagnosed with type 2 diabetes than those on placebo: 1.3% versus 13.3%, a hazard ratio of 0.07. Weight loss remained substantial throughout, averaging 19.7% at the highest dose.6

That is a striking result, and it raises a harder question: who should receive a medication for years before a disease appears? Preventive treatment at population scale depends on tolerability, cost, insurance coverage, supply and willingness to stay on therapy — none of which are answered by an efficacy trial. Diabetes prevention may be one of the most important uses of these drugs, and it is also the one most sensitive to whether the evidence base can support long-term use in people who currently feel well.

6. Muscle preservation may become the field's most important problem

Weight loss is not homogeneous. When people lose weight on a GLP-1, a substantial share of the loss is lean tissue — muscle, organ mass and water — not only fat. Interim results from the phase 2 COURAGE trial estimated that approximately 35% of semaglutide-induced weight loss came from lean mass.15 That proportion is broadly consistent with what is seen after bariatric surgery and with ordinary calorie restriction, which is itself the point: the issue is not that GLP-1s are uniquely destructive to muscle, but that the field's expectations for body composition have changed.

This matters most for adults over 50, whose margin of safety in muscle and bone is thinner. Age-related muscle loss — sarcopenia — is defined by low muscle strength with low muscle quantity and quality, and it is associated with falls, disability and worse outcomes from illness.13 Losing lean mass while improving metabolic markers may still be a net gain, but it is a different trade-off than the trial endpoints capture, and it is a trade-off that compounds over repeated cycles of loss and regain.

That gap is now a therapeutic target. Preclinical work showed that blocking activin type II receptors preserves skeletal muscle mass and enhances fat loss during GLP-1 receptor agonism.14 In the COURAGE trial, adding muscle-preserving antibodies to semaglutide protected roughly 50% to 80% of the lean mass that semaglutide alone would have cost, while increasing fat loss.15 A phase 2 study of tirzepatide combined with bimagrumab is underway. None of these combinations is approved.

For an individual reader, the implication is straightforward and available today: the intervention with the best evidence for protecting muscle during GLP-1 weight loss is resistance training with adequate protein, and it does not depend on any drug that is still in development.

7. Maintenance after weight loss may become its own science

Obesity behaves as a chronic biological condition. When weight is lost, the body defends the previous level: appetite signaling rises, energy expenditure falls, and weight regain is the common outcome without continued intervention. Trials that pull participants off therapy show rapid regain — in SURMOUNT-1, blood glucose markers and body weight moved back toward baseline during the off-treatment period.6

So the open questions are no longer about the first year. They are about maintenance doses: whether the dose that produced loss is the dose required to hold it, whether patients can transition to a less intensive or oral therapy, whether structured exercise and nutrition can substitute for continued pharmacotherapy in some people, and how to identify who needs lifelong support versus who does not. Trial designs that stop at 72 weeks answer none of these.

This is also where the conversation about drug shortages, insurance coverage and out-of-pocket cost becomes a clinical question rather than a financial one. A therapy whose benefit depends on continuity is a different kind of product than a course of treatment.

8. GLP-1s and longevity: a promising concept, an unproven claim

The longevity argument is coherent. These medications reduce major cardiovascular events, protect kidney function, resolve liver inflammation, lower inflammation and can prevent progression to type 2 diabetes. Cardiovascular disease, kidney disease and diabetes are among the largest drivers of mortality in high-income countries, so improving them plausibly extends life.

The first direct test of one specific claim came back negative. evoke and evoke+ were two identical, duplicated phase 3 trials of oral semaglutide in early symptomatic Alzheimer's disease, together randomizing 3,808 participants. Neither found a significant slowing of clinical disease progression on the primary measure, although amyloid biomarkers moved in the expected direction.11, 12 Because the two trials were designed to corroborate each other, a consistent negative result is difficult to explain as noise.

The distinction that follows is the one GLP1 Academy keeps returning to. These medicines are becoming multisystem cardiometabolic therapies with genuine disease-modifying effects. Whether they slow human biological aging is a separate question, and it is currently a hypothesis rather than a finding. Marketing a GLP-1 as a proven longevity drug overstates the evidence, and a reader who pays for it on that promise is buying something the trials have not delivered.

9. Personalization is likely to replace the one-drug-for-everyone model

Two people with identical BMI can have very different reasons for their weight, very different tolerability limits and very different risk profiles. One may have predominant appetite-based eating, another a low metabolic rate; one may benefit enormously from cardiovascular protection, another from kidney or liver effects. A single medication chosen by body-mass index alone is a blunt instrument.

As the options multiply, the selection problem becomes the clinical problem. Matching a therapy to a phenotype, existing conditions, treatment goals, side-effect tolerance and long-term risk is what a prescriber is for, and it is a reasonable question to bring to an appointment: given my labs, my cardiovascular and kidney risk, my other medications and my goals, which of these is the right one for me, and what happens if I stop?

The same logic applies to what the consumer can control. If the outcome that matters is body composition rather than scale weight, then the prescription worth writing yourself — resistance training two or more times a week, adequate protein, sleep — is the one that helps whichever medication you are taking.

10. The GLP-1 revolution is becoming something bigger

The label is starting to fit badly. The field now includes GLP-1/GIP dual agonists, GLP-1/GIP/glucagon triple agonists, GLP-1/amylin therapies, amylin combinations and small-molecule oral agonists, alongside GLP-1 receptor agonists themselves. Calling all of it 'GLP-1' understates what has happened.

The endpoints are changing too. The question has moved from 'does it lower blood glucose?' to 'does it prevent heart attacks?', 'does it protect the kidneys?', 'does it improve liver disease?', 'does it prevent diabetes?', 'can patients maintain the benefits?' and 'can it reduce excess fat without sacrificing muscle?' Each of those is a different definition of success, and the field is now measuring against all of them.

The most useful lesson is methodological rather than clinical. Across every one of these developments, the same discipline applies: separate what a trial actually measured from what a headline claims, and separate what is proven in humans from what is plausible. That habit is worth more than any single result on this page, because the next set of results will arrive within months.

What this means if you're on a GLP-1 today

The research above is encouraging, but almost none of it changes what you can do this month. Three things follow directly from the evidence:

  1. 1Protect muscle now. Resistance training and adequate protein are the interventions with the strongest human evidence for preserving lean mass during weight loss, and they don't depend on a drug still in phase 2.
  2. 2Ask about the whole picture, not the scale. Cardiovascular risk, kidney function, liver health, muscle and strength are what the new trials measure — and they are the right questions for your own care.
  3. 3Plan maintenance from the start. Regain is the common outcome when therapy stops, so a plan for after the target weight is not an afterthought.

Frequently asked questions

What's next for GLP-1s?

Three things are furthest along: oral formulations that remove the injection barrier, multi-hormone agonists that push weight loss higher (retatrutide reached 20.8% and 22.6% body-weight reduction in two phase 3 trials), and combinations with amylin agonists such as cagrilintide. In parallel, regulators have approved GLP-1 therapies for cardiovascular risk reduction, kidney protection and MASH liver disease.

Is there an oral GLP-1 pill?

Oral semaglutide already exists at a low dose for type 2 diabetes. The next step is a higher-dose 50 mg tablet: in the SOUL trial of 9,650 adults with type 2 diabetes at high cardiovascular risk, it reduced major cardiovascular events to 12.0% versus 13.8% on placebo. That application is under FDA review, and small-molecule oral agonists are in earlier trials.

Are GLP-1 drugs longevity drugs?

Not yet, on the evidence available today. They lower cardiovascular and kidney events and may prevent diabetes — all of which influence lifespan. But the direct test of a dementia outcome came back negative: evoke and evoke+ found oral semaglutide did not significantly slow clinical progression in early symptomatic Alzheimer's disease. Biological plausibility is not proof.

A note on the evidence

This article summarizes published trial results and company disclosures as of October 2026, and describes investigational medications that are not approved or available. A result in a controlled trial is not a recommendation for any individual, and the magnitude of benefit seen in a trial population will not match any single person's experience. Medication decisions — including whether to start, continue, change or stop a GLP-1 — belong between you and your prescribing healthcare professional, based on your own history, labs, other medications and goals.

References

Peer-reviewed trial reports, regulatory documents and company disclosures supporting this article. Numbers in the text link here.

  1. 1Lincoff AM, et al. "Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes" (SELECT). New England Journal of Medicine, 2023. View source →
  2. 2Pericic D, et al. "Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes" (FLOW). New England Journal of Medicine, 2024. View source →
  3. 3U.S. Food and Drug Administration. "FDA Approves Treatment for Serious Liver Disease Known as 'MASH'." August 15, 2025. View source →
  4. 4Novo Nordisk A/S. Form 6-K: Wegovy approved in the US for the treatment of MASH, with ESSENCE part 1 results. August 15, 2025. View source →
  5. 5McGuire DK, et al. "Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes" (SOUL). New England Journal of Medicine, 2025. View source →
  6. 6"Tirzepatide for Obesity Treatment and Diabetes Prevention" (SURMOUNT-1, 176-week analysis). New England Journal of Medicine, 2025. View source →
  7. 7Bellido V, et al. "Retatrutide in adults with obesity and type 2 diabetes" (TRIUMPH-2). The Lancet, 2026. View source →
  8. 8Eli Lilly and Company. "Lilly's triple agonist retatrutide successful in two additional phase 3 trials," including TRIUMPH-3 and the planned filing. July 23, 2026. View source →
  9. 9Rosenblatt S, et al. "Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity" (REDEFINE 1). New England Journal of Medicine, 2025. View source →
  10. 10Novo Nordisk U.S. "Zenagamtide Phase 2 T2D Data at ADA 2026." June 5, 2026. View source →
  11. 11Cummings JL, et al. "Oral semaglutide in early-stage symptomatic Alzheimer's disease" (evoke and evoke+). The Lancet, 2026. View source →
  12. 12Novo Nordisk A/S. Form 6-K: outcome of the evoke and evoke+ trials. November 24, 2025. View source →
  13. 13Cruz-Jentoft AJ, et al. "Sarcopenia: revised European consensus on definition and diagnosis" (EWGSOP2). Age and Ageing, 2019. View source →
  14. 14Holman CD, Baur JA, Titchenell PM. "Antibody blockade of activin type II receptors preserves skeletal muscle mass and enhances fat loss during GLP-1 receptor agonism." Molecular Metabolism, 2024. View source →
  15. 15Regeneron Pharmaceuticals. "Interim Results from Ongoing Phase 2 COURAGE Trial," June 2, 2025. View source →

Related reading

Brought to you by GLP1 Academy, an independent consumer education platform from Longevity Academy. We do not prescribe or sell medications.